Founder · Executive · Scientist
Joanna Stanicka
Joanna Stanicka is the co-founder, president and CEO of Axonis Therapeutics, a Boston clinical-stage biotech developing first-in-class oral medicines that target the brain chloride transporter KCC2 to treat epilepsy, neuropathic pain and spinal cord injury. A Harvard-trained neuroscientist who began her career in cancer biology in Ireland, she moved from the bench to the boardroom, taking Axonis from a Boston Children's Hospital discovery to a company that raised a $115 million Series A in 2024 and pushed its lead drug, AXN-027, into first-in-human trials.